739 related articles for article (PubMed ID: 23212593)
1. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
Tanaka Y; Yamaoka K
Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
Tanaka Y; Maeshima K; Yamaoka K
Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
[TBL] [Abstract][Full Text] [Related]
4. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH
Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202
[TBL] [Abstract][Full Text] [Related]
5. Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.
Tanaka Y
J Biochem; 2015 Sep; 158(3):173-9. PubMed ID: 26152731
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
Gupta AK; Cernea M; Lynde CW
Skin Therapy Lett; 2017 Mar; 22(2):1-7. PubMed ID: 28329404
[TBL] [Abstract][Full Text] [Related]
7. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
Fleischmann R; Cutolo M; Genovese MC; Lee EB; Kanik KS; Sadis S; Connell CA; Gruben D; Krishnaswami S; Wallenstein G; Wilkinson BE; Zwillich SH
Arthritis Rheum; 2012 Mar; 64(3):617-29. PubMed ID: 21952978
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib for treatment of rheumatoid arthritis.
Rakieh C; Conaghan PG
Adv Ther; 2013 Aug; 30(8):713-26. PubMed ID: 23943546
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
[TBL] [Abstract][Full Text] [Related]
10. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.
Wollenhaupt J; Silverfield J; Lee EB; Curtis JR; Wood SP; Soma K; Nduaka CI; Benda B; Gruben D; Nakamura H; Komuro Y; Zwillich SH; Wang L; Riese RJ
J Rheumatol; 2014 May; 41(5):837-52. PubMed ID: 24692527
[TBL] [Abstract][Full Text] [Related]
12. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
[TBL] [Abstract][Full Text] [Related]
13. A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate.
Fleischmann R
Expert Opin Pharmacother; 2017 Oct; 18(14):1525-1533. PubMed ID: 28829236
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials.
Song GG; Bae SC; Lee YH
Korean J Intern Med; 2014 Sep; 29(5):656-63. PubMed ID: 25228842
[TBL] [Abstract][Full Text] [Related]
16. Summaries for patients: tofacitinib for the treatment of rheumatoid arthritis.
Ann Intern Med; 2013 Aug; 159(4):I-26. PubMed ID: 24026272
[No Abstract] [Full Text] [Related]
17. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.
Tanaka Y; Suzuki M; Nakamura H; Toyoizumi S; Zwillich SH;
Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1150-8. PubMed ID: 21584942
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib versus methotrexate in rheumatoid arthritis.
Lee EB; Fleischmann R; Hall S; Wilkinson B; Bradley JD; Gruben D; Koncz T; Krishnaswami S; Wallenstein GV; Zang C; Zwillich SH; van Vollenhoven RF;
N Engl J Med; 2014 Jun; 370(25):2377-86. PubMed ID: 24941177
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Vyas D; O'Dell KM; Bandy JL; Boyce EG
Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S
Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]